TG Therapeutics
TGTX
83 hedge funds and large institutions have $283M invested in TG Therapeutics in 2015 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 15 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 25
8% less funds holding
Funds holding: 90 → 83 (-7)
21% less call options, than puts
Call options by funds: $1.34M | Put options by funds: $1.71M
29% less capital invested
Capital invested by funds: $396M → $283M (-$114M)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.1M |
| 2 |
BM
Bridger Management
New York
|
+$22.6M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$10.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.09M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$6.81M |
| 2 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$6.31M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.65M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.36M |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$1.98M |
TGTX Hedge Fund Activity: Q3 2015 in Review
83 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2015, worth a combined $283M — down 29% from $396M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TGTX and 8 opened new positions — a net loss of 7 holders — while 25 trimmed existing stakes and 37 added.
The largest buyer was Fidelity Investments, adding an estimated $31.1M. The largest seller was EAM Investors, exiting entirely with an estimated $6.81M sold.
- 83 institutional investors held TG Therapeutics (TGTX) as of Q3 2015, down from 90 in Q2 2015.
- Funds reported $283M of TG Therapeutics stock for Q3 2015, down 29% quarter-over-quarter.
- 8 funds opened new TG Therapeutics positions in Q3 2015 and 15 closed out, a net change of -7 holders.
- The largest TG Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $31.1M added.
- The largest TG Therapeutics seller in Q3 2015 was EAM Investors, an estimated $6.81M sold.
Based on aggregated 13F filings for Q3 2015.